Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2019, Article ID 2034950, 6 pages
https://doi.org/10.1155/2019/2034950
Research Article

Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal

Department of Rheumatology, National Center for Rheumatic Diseases (NCRD), 44600, Nepal

Correspondence should be addressed to Binit Vaidya; moc.oohay@aydiavtinibrd

Received 24 December 2018; Revised 1 February 2019; Accepted 24 February 2019; Published 1 April 2019

Academic Editor: Lazaros I. Sakkas

Copyright © 2019 Binit Vaidya and Shweta Nakarmi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Dobler, “Biologic agents and tuberculosis,” Microbiology Spectrum, vol. 4, no. 6, Article ID TNMI7-0026-2016, 2016. View at Google Scholar
  2. R. Handa, S. Upadhyaya, S. Kapoor et al., “Tuberculosis and biologics in rheumatology: a special situation,” International Journal of Rheumatic Diseases, vol. 20, no. 10, pp. 1313–1325, 2017. View at Publisher · View at Google Scholar
  3. F. Cantini, C. Nannini, L. Niccoli et al., “Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice,” Autoimmunity Reviews, vol. 14, no. 6, pp. 503–509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Akgul and S. Ozgocmen, “Classification criteria for spondyloarthropathies,” World Journal of Orthopedics, vol. 2, no. 12, pp. 107–115, 2011. View at Publisher · View at Google Scholar
  5. D. van der Heijde, S. Ramiro, R. Landewé et al., “2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 76, no. 6, pp. 978–991, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. WHO, “Guidelines on the management of latent tuberculosis,” 2015. http://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf.
  7. S. H. Lee, “Diagnosis and treatment of latent tuberculosis infection,” Tuberculosis and Respiratory Diseases, vol. 78, no. 2, pp. 56–63, 2015. View at Publisher · View at Google Scholar
  8. A. Malaviya, R. Thakaran, R. Rawat et al., “Real life experience of a screening strategy for latent tuberculosis before treatment with biologicals in indian patients with rheumatic diseases,” Indian Journal of Rheumatology, vol. 13, no. 4, pp. 233–239, 2018. View at Publisher · View at Google Scholar
  9. GBD Tuberculosis Collaborators, “The global burden of tuberculosis: results from the global burden of disease study 2015,” The Lancet Infectious Diseases, vol. 18, no. 3, pp. 261–284, 2018. View at Google Scholar
  10. National Tuberculosis Center, “National tuberculosis program. Annual report 2073/74 (2017),” Tech. Rep., Government of Nepal, Ministry of Health & Population, Department of Health Services, National Tuberculosis Center, 2017. View at Google Scholar
  11. World bank economy classification by country. http://gi.org/wp-content/uploads/2018/01/World-Bank-Country-List-Low-and-Lower-Middle.pdf.
  12. X. Xie, F. Li, J.-W. Chen, and J. Wang, “Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside,” Journal of Microbiology, Immunology and Infection, vol. 47, no. 4, pp. 268–274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Singh, G. A. Wells, and R. Christensen, “Adverse effects of biologics: a network meta-analysis and cochrane overview,” Cochrane Database of Systematic Reviews, vol. 16, no. 2, Article ID CD008794, 2011. View at Publisher · View at Google Scholar
  14. D. A. Silva, M. V. Silva, C. C. Barros et al., “TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines,” PLoS ONE, vol. 13, no. 3, Article ID e0194430, 2018. View at Publisher · View at Google Scholar
  15. T. Hasan, E. Au, S. Chen, A. Tong, and G. Wong, “Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines,” BMJ Open, vol. 8, no. 9, Article ID e022445, 2018. View at Publisher · View at Google Scholar
  16. C. H. Smith, A. V. Anstey, J. N. W. N. Barker et al., “British association of dermatologists' guidelines for biologic interventions for psoriasis 2009,” British Journal of Dermatology, vol. 161, no. 5, pp. 987–1019, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Denholm, “The use of anti-tuberculosis therapy for latent TB infection,” Infection and Drug Resistance, vol. 3, pp. 63–72, 2010. View at Publisher · View at Google Scholar
  18. F. Iannone, F. Cantini, and G. Lapadula, “Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations,” The Journal of Rheumatology, vol. 41, no. 91, pp. 41–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Duarte, S. Campainha, J. Cotter et al., “Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy,” Acta Reumatológica Portuguesa, vol. 37, no. 3, pp. 253–259, 2012. View at Google Scholar
  20. P. Mease, J. Sieper, F. Van den Bosch, P. Rahman, P. M. Karunaratne, and A. L. Pangan, “Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis,” Arthritis & Rheumatology, vol. 67, no. 4, pp. 914–923, 2015. View at Publisher · View at Google Scholar
  21. J. Sieper, D. van der Heijde, M. Dougados et al., “Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1),” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 815–822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. Edwards, B. Fautrel, H. Schulze-Koops, T. W. Huizinga, and K. Kruger, “Dosing down with biologic therapies: a systematic review and clinicians’ perspective,” Rheumatology, vol. 56, no. 11, pp. 1847–1856, 2017. View at Publisher · View at Google Scholar